Merck, Google Cloud launch $1 billion agentic AI partnership for operations

Merck did not just buy another AI tool. It agreed to spend up to $1 billion with Google Cloud on an agentic platform that will run across research and development, manufacturing, commercial, and corporate functions, with Google Cloud engineers embedded alongside Merck teams.

The companies announced the deal on April 22 at Google Cloud Next 2026 in Las Vegas. The rollout will use Gemini Enterprise and related Google Cloud AI infrastructure, and Merck said the goal is to strengthen its digital backbone as an AI-enabled enterprise. Merck, which says it has about 75,000 employees worldwide and is known as MSD outside the United States and Canada, is making a long-term bet that AI only matters if it changes how work actually gets done.

That is the lesson Monday.com workers should notice. In heavily regulated environments, the winning AI story is not a slick assistant sitting on top of old processes. It is process design: who can trigger an action, what data the agent can see, how every step is logged, and how compliance teams can audit the outcome later. Merck’s scope matters because it spans the messy parts of enterprise operations, where permissions, traceability, and validation are not optional extras. For product teams, that raises the bar for enterprise AI features. For sales teams, it changes the conversation from “what can the model do?” to “can this platform orchestrate work across regulated systems without breaking controls?”

Google Cloud used the same conference to push its broader agentic agenda, saying Cloud Next 2026 drew more than 32,000 leaders, developers, and partners. The company also unveiled Gemini Enterprise Agent Platform, Agentic Data Cloud, Agentic Defense and other products meant to help customers build, govern, and optimize agents across enterprise workflows. In that context, Merck is less a one-off customer win than a proof point for a larger market shift: buyers are being asked to rewire operating models around agents, not merely add AI features to existing software.

Trade coverage has described the Merck deal as one of the largest agentic AI deployments in pharma, which helps explain why the implementation model matters as much as the headline number. A multi-year rollout of this size suggests a long runway of integration work, governance review, and change management, not a short pilot. That is the kind of buying pattern that should resonate inside monday.com, where the next wave of enterprise adoption will likely depend on whether the platform can make AI not just useful, but accountable, audit-ready, and embedded in the daily flow of work.